DNA Script Awarded $2.7M in Innovation Grants From Bpifrance — Total Financing Raised to Date Is $27M
DNA Script announced today it has been awarded $2.7M in non-dilutive financing from the “Concours d’Innovation” program of Bpifrance. DNA Script was awarded this financing, to be received as subsidies and refundable advances, based on the promise of the company’s innovative enzymatic DNA synthesis technology and on the company’s potential to become a global leader in biomanufacturing for cell and gene therapy.
As the field of genomics accelerates, innovative genome editing technologies are driving advancements in life sciences research. The market for synthetic nucleic acids has expanded to over $1 billion per year globally, but the demand is not always met. For the past 50 years, synthetic DNA has been manufactured through a complex chemical process with limitations in terms of quality, turn-around time and manufacturing flexibility. In contrast, DNA Script introduces a novel biochemical process for DNA and RNA synthesis based on the use of highly efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals. It will in particular enable the production of long DNA constructs, which are a key component of cell and gene therapy drugs.
“In the past few years, cell and gene therapy, as well as gene editing approaches, have showed promising results in the clinic. However, manufacturing such drugs is often a challenge. There is an unmet need for high quality, quickly manufactured synthetic DNA. Through this new financing, BPIFrance will enable the company to further demonstrate the potential of the technology for manufacturing long DNA constructs at scale,” said Thomas Ybert, PhD, CEO and co-founder of DNA Script.
“We are proud to support DNA Script in the development of this technology. This young French company has everything it needs to become a world leader in this extremely promising field,” said Virginie Fontaine from Bpifrance.
DNA Script is one of eight companies to receive an award for the “Concours d’Innovation 2018” of Bpifrance in the “Healthcare” division. This competitive grant is dedicated to innovative projects aimed at accelerating the emergence of companies with the potential to become world leaders in their respective markets.
Ybert added: “We see our project to set a gold standard for efficient, clean DNA synthesis as a great example of several high-value applications which will benefit from DNA Script’s core platform technology in the coming years.”
To date, DNA Script has raised a total of $27M. In September 2017, DNA Script announced a Series A financing round of $13 million led by Illumina Ventures, with additional investments from M Ventures — the corporate venture arm of Merck KGaA, Darmstadt, Germany — and existing investors Sofinnova Partners, Kurma Partners and Idinvest Partners.
About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script’s approach leverages billions of years of natural evolution to enable genome-scale synthesis. The company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops and DNA data storage. www.dnascript.co
A subsidiary of the Caisse des Dépôts (French Consignments and Loans Fund) and the State, a trusted partner of entrepreneurs, Bpifrance supports companies from start-up to stock exchange listing, with credit, collateral and equity. Bpifrance also provides support services and enhanced support for innovation, acquisitions and exports, in partnership with Business France. Bpifrance offers companies a continuum of funding at each key stage of their development and an offer adapted to regional specificities. With 47 regional offices (90% of its decisions are taken at the regional level) Bpifrance is a tool of economic competitiveness for entrepreneurs. Bpifrance supports public policies pursued by the French State and by Regional Councils to meet three objectives: support the growth of businesses; prepare future competitiveness; contribute to the development of a favorable ecosystem for entrepreneurship. With Bpifrance, companies benefit from an influential, available and effective intermediary to meet all their needs in terms of finance, innovation and investment.
For further information, please visit: www.bpifrance.fr
Press contact in the US
Lisa Rodriguez, 415-505-5447
Press contacts in Europe
Caroline Carmagnol and Tatiana Vieira, 06 64 18 99 59 / 01 44 54 36 65
DNA Script Contact
Sylvain Gariel, COO
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia26.4.2019 11:30:00 CEST | Pressemelding
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation. The safety and efficacy results provided in the application are from the pivotal phase 3 studies MEDALIST and BELIEVE, evaluating the ability of luspatercept to effectively address anemia associated with MDS and beta-thalassemia, respectively. “As a first-in-class erythroid maturation ag
SES: First Quarter 2019 Results26.4.2019 06:00:00 CEST | Pressemelding
SES S.A. announced its financial results for the three months ended 31 March 2019 with revenue and EBITDA in line with company expectations and SES on track to deliver on its 2019 financial outlook. Continued focus on execution has delivered major wins in the Networks business which is soon to be enhanced with the addition of four new O3b satellites, successfully launched at the beginning of April 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005955/en/ First Quarter 2019 Results Key financial highlights Reported revenue of EUR 480.6 million, (down 2.3% at constant FX(1)) in line with SES’ expectations Underlying revenue(2) of EUR 473.9 million; down 3.1%(1) (Video: -7.3%(1,2) and Networks +5.4%(1,2)) EBITDA of EUR 290.1 million representing a margin of 60.4% (Q1 2018: 63.7%); 62.1% excluding restructuring charge Net profit attributable to SES shareholders of EUR 72.2 million Free Cash Flow before financing acti
Wenco and Hitachi Construction Machinery Announce Open and Interoperable Partner Ecosystem for Autonomous Mining25.4.2019 23:30:00 CEST | Pressemelding
Hitachi Construction Machinery Co., Ltd. (TOKYO: 6305) (“HCM”) is pleased to announce its vision for autonomous mining — an open, interoperable ecosystem of partners that integrate their systems alongside existing mine infrastructure. Grounded in support for ISO Standards and a drive to encourage new entrants into the mining industry, HCM is pioneering this open and interoperable approach to autonomy among global mining technology leaders. With this announcement, HCM is publicly declaring support for standards-based autonomy and is offering its interoperable technology to assist mining customers in integrating new vendors into their existing infrastructure. HCM’s support for open, interoperable autonomy is based on its philosophy for its partner-focused Solution Linkage platform. “Open innovation is the guiding technological philosophy for Solution Linkage,” says Vice President and Executive Officer, Chief Technology Officer Hideshi Fukumoto. “Based on this philosophy, HCM is announcin
Garth Brooks Makes Mobile Game Debut in Words With Friends, Announces Final Pre-Order Window for The Legacy Collection25.4.2019 19:30:00 CEST | Pressemelding
Today, Zynga Inc. (Nasdaq: ZNGA), global leader in interactive entertainment, announced a collaboration with Garth Brooks, in its hit game, Words With Friends 2 . Kicking off a multi-month celebration of the game franchise’s 10th anniversary, and Brooks’ unprecedented career as a recording artist, players and fans will be treated to Garth-themed in-game activities and ongoing announcements starting with today’s reveal of ‘Journey’ as the game’s ‘Word of the Year’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005903/en/ Garth Brooks LEGACY COLLECTION (Graphic: Business Wire) Garth Brooks and Words With Friends are celebrating their 2019 milestones by giving fans new ways to interact with Garth and the game. On May 1st, Brooks will co-host Words With Friends LIVE, the nightly trivia game broadcast within Words With Friends 2. In conjunction, the FINAL pre-order window for special numbered editions of The Legacy Collect
Nordson EFD Introduces the Contact versus Jet Dispensing White Paper25.4.2019 12:16:00 CEST | Pressemelding
Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce its Contact vs. Jet Dispensing white paper. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005027/en/ As products continue to get smaller and smaller, Nordson EFD has developed new solutions to address this growing need to apply precise, repeatable micro-deposits of assembly fluids in production processes worldwide. “We understand the challenges manufacturers face when their process requires bonding tiny substrates and components together,” said Peter Langer, Business Unit Director of Valves at Nordson EFD. “The deposit tolerance requirements are considerable. And there are a number of variables to consider in order to choose the right dispensing method.” This white paper helps manufacturers understand the difference between two of the most common dispensing methods. Contact dispe
Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe25.4.2019 12:15:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005180/en/ Trident® HD Specimen Radiography System (Photo: Business Wire) The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system, which recently received FDA clearance in the US and a CE Mark in Europe, also features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy sa